How to Determine the Product Classification for Overseas Registration of Rehabilitation Devices

Executive Summary

The first step in overseas registration of rehabilitation devices is to accurately determine the product classification. This directly determines the registration pathway, technical documentation requirements, and time-to-market. Companies should first confirm whether the device falls within the scope of medical device regulation in the target country, and then map its intended use, principle of operation, and risk level against local classification rules. Categories are typically I, IIa/IIb, or Class A/B/C. When making this determination, do not rely solely on the NMPA category or simply copy the CE classification. The governing regulation of the target market must be followed. Common references include FDA 21 CFR 862–892, EU MDR 2017/745, MHLW classification, and official directories in Southeast Asia, the Middle East, and Latin America. A classification error can lead to application rejection, prolonged deficiency periods, or post-market regulatory penalties. It is recommended that companies first establish a product description and intended-use document, review the regulatory basis, form a classification rationale report, and then assess the reusability of existing NMPA, CE, ISO 13485, MDSAP, and other documentation. Key risk points include failing to confirm local agent or authorized representative requirements, neglecting localized labeling and instructions for use, and not planning post-market surveillance and renewal processes. For registrations in GHWP member states and multi-country submissions, core technical documents should be centrally managed and localized per country requirements to reduce redundant work.

Compiled from the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's own documentation.

Applicable Scenarios and Core Issues

Rehabilitation devices are a high-frequency category in medical device exports, covering physical therapy devices, exercise training equipment, walking assist devices, cognitive training systems, rehabilitation robots, and traditional Chinese medicine rehabilitation devices. Because the product forms and intended uses vary widely, the first challenge companies face when applying for overseas registration is not preparing documentation, but determining the classification level in the target market. A wrong classification decision can misdirect all subsequent work.

The core issue here is not “how to label the product,” but clarifying the regulatory boundary. Different countries or regions define and classify “rehabilitation devices” differently. They may be medical devices, health devices, assistive products, or even ordinary consumer goods. If a company only looks at the Chinese NMPA classification or the EU CE classification and assumes it is universally applicable, the risk is high.

This article is intended for companies preparing to enter GHWP member states, Southeast Asia, the Middle East, Latin America, and other markets. It provides a classification decision logic based on product risk attributes and intended use, and explains how to leverage existing certificates, test reports, and system certifications as supporting evidence for classification in overseas registrations.

Registration Classification Logic

Classification determination should follow four progressive steps.

Step 1: Confirm whether the product is a medical device in the target country

For the United States, check whether it meets the definitions under the FD&C Act, such as “instrument, apparatus, implement,” and cross-reference the FDA product classification database. In the EU, screen against the MDR definition of a medical device or an accessory to a medical device. In Southeast Asian countries such as Thailand, the Philippines, and Vietnam, each has its own description of “medical device.” Some countries also regulate software used for rehabilitation as a medical device.

Step 2: Determine the risk class

Most markets adopt a system similar to the EU (I, IIa, IIb, III) or the US FDA (I, II, III). Risk classification depends on the principle of operation, invasiveness, energy delivery, need for external monitoring, and whether the device contains medicinal or biological substances. Common rehabilitation devices with risks include energy-based equipment such as electrical stimulation, laser, ultrasound, and magnetic therapy. These are usually not lower than IIa or Class II. Non-powered mobility assist devices may be low risk, but if they include electronic control systems, the risk class will be higher.

Step 3: Reference the target market's classification directory or rules

The EU MDR uses rules to classify devices. The US FDA has a database based on intended use and device codes. Japan's PMDA uses JMDN codes. Southeast Asian countries often refer to EU, US, or IMDRF classifications. Your regulatory team should establish the classification basis for each target country and create a traceable comparison table.

Step 4: Assess the reusability of existing documentation

If the product already holds an NMPA registration certificate, CE certificate, or FDA 510(k), compare the technical specifications and intended use point-by-point. For example, a low-frequency therapy device classified as Class II in China may require more rigorous clinical data in South Korea, or additional local testing in Saudi Arabia. Whether existing data can be reused depends on a comparison of safety characteristics and performance standards, and cannot be decided arbitrarily.

For multi-country registrations or under the GHWP framework, a “master file + country-specific difference file” model is recommended. The master technical document covers all hard requirements, and then labeling, instructions for use, local agent information, application format, and certificate holder identity are adjusted by country. Classification determination must be embedded in the technical documentation, with the classification rationale report serving as the starting document.

Documentation and Evidence

After completing the classification determination, companies need to prepare a documentation package that supports the classification conclusion. First, prepare a complete product description, including design principle, materials, mechanism of action, intended use, contraindications, environment of use, and operator profile. All classification filings must be based on this description, and it should not be altered later.

Second, provide a list of applicable standards. Common test standards for rehabilitation devices include the IEC 60601 series, ISO 14971 risk management, ISO 10993 biocompatibility, and relevant mechanical strength standards. Passing standard tests is core evidence for proving safety and corroborating the risk class. If the product is Class IIa under the EU MDR, a clinical evaluation compliant with MDR must be completed. If it is Class B in Malaysia, equivalence justification or clinical trial data may be required.

Quality system certificates are also important evidence. An ISO 13485 certificate is accepted by almost all markets. MDSAP can reduce some on-site audits, but check that the certificate scope covers the design and manufacturing sites of the target product. If the classification determination requires a factory inspection, the quality system certificate and MDSAP status need to be updated in advance.

Labels and instructions for use samples should also be prepared. Depending on market requirements, label content must include the manufacturer, agent, CE or local certification number, and usage warnings. During the classification filing stage, the “intended use” statement on the label must be fully consistent with the classification basis; otherwise, reviewers may question the accuracy of the classification.

A local agent agreement or authorization letter is indispensable. The EU, Middle East, and most Southeast Asian countries require an in-country representative or the certificate holder. Companies should provide the authorization agreement and the local agent's qualification documents. Post-market surveillance plans and vigilance system documents are also required by many regulators and are checked during classification review.

Finally, the classification rationale report must explain the regulatory basis and reasoning for each step. This report is not an “exam paper” for regulators, but an internal decision document for determining the pathway, and a shared base document for multi-country registrations. It is recommended that it be reviewed by regulatory personnel or consultants with experience in the target country's registration.

Common Mistakes

• Directly using the NMPA classification as the basis for overseas registration without comparing local regulations, leading to classification deviations. For example, a Class I product in China may be Class II in the US and require a 510(k) submission.
• Over-reliance on CE classification. CE classification has only four levels (I, IIa, IIb, III), while FDA classification or some Asian countries' systems are different and cannot be directly converted.
• Inaccurate intended use descriptions. Some companies describe rehabilitation devices as fitness equipment to obtain a lower risk classification, which later results in registration scope that does not cover actual use, creating compliance risks.
• Ignoring the impact of software or algorithms on classification. Cognitive training or rehabilitation assessment software may be an independent medical device or a health application in different markets. Whether it has decision-support functions can directly change the classification.
• Using outdated standards or obsolete regulations as the classification basis. After the EU transition to MDR, some certificates are no longer valid. Citing a withdrawn MDD certificate may lead to the application being rejected.
• Ignoring the special definition of “rehabilitation” in the target country. For example, Japan classifies some assistive devices as “non-medical devices,” while Thailand may classify them as “medical devices.” Without local research, companies may misjudge.
• Failing to provide a classification rationale report, or submitting only a statement claiming “low risk” without regulatory references. Reviewers will usually reject or request supplementary information.
• Not confirming the scope of the local agent's registration. Some countries require the agent to hold a local registration qualification or license. Signing an agreement without verifying this may lead to difficulties in future changes.

Company Preparation Checklist

• Define the product name, intended use, and principle of operation, and create a product description document in English and the target country's language.
• Collect the current medical device regulations and classification guidance of the target country, including official links and issuing bodies.
• Create a comparison table of the product against the target country's classification rules, noting the classification basis for each item.
• Gather existing NMPA approvals, CE certificates, FDA 510(k) or registration certificates as historical evidence.
• Confirm the scope of your ISO 13485 certificate, and expand the certification scope in advance if necessary.
• Obtain relevant test reports, including EMC, electrical safety, biological evaluation, and software lifecycle documents.
• Prepare risk management reports and clinical evaluation reports, ensuring they match the classification category.
• Create label and instructions for use versions for different countries, paying special attention to local language and regulatory requirements.
• Identify the local authorized representative or local agent, and prepare contracts, letters of authorization, and agent qualification evidence.
• Develop a post-market surveillance plan and an adverse event reporting process as part of the registration dossier.
• Establish a multi-country registration project table recording each country's classification decision, submission status, and renewal dates.
• When classification is uncertain, request pre-submission consultation or formal pre-review communication with the target country's regulatory authority.

AIMEILI Perspective

As a regulatory consultancy that has long served medical device exports, AIMEILI has observed that the most common misjudgment in overseas classification is directly transplanting “Chinese experience” to the target market. Companies often believe that because they have obtained a Chinese Class II registration, they will be able to complete overseas filing at the same risk level. This habitual way of thinking leads to subsequent deficiencies and timeline losses.

The most important thing in the early stage of a project is not translation and submission, but forming a small team that includes target-country regulatory, clinical evaluation, standards testing, and local agent resources, and using a common template to complete the classification rationale. Within the first two weeks of project initiation, you should lock in the classification conclusion for each market and synchronize it into the product development plan.

Regarding data reuse, we need to clarify the principle: general technical data, such as product design documents, risk management reports, and basic safety standard test reports, can be reused across all markets. But classification rationale, intended use descriptions, clinical evaluation reports, labels, and instructions for use must be localized according to local regulations. Even for GHWP member states, a local applicability analysis cannot be omitted.

The importance of the local agent and certificate control should not be underestimated. If a company entrusts a trading company or reseller as the permanent agent, it may lose control of the certificate, and subsequent changes to permissions, addresses, or renewals may be hindered. We recommend choosing a qualified authorized representative and clearly defining certificate ownership, data access, and termination clauses in the contract.

In multi-country registration projects, the biggest cost comes from redundant work. You should establish a master technical document library, manage shared documents by chapter, and then set up difference files for each country. This satisfies each country's requirements and prevents starting from scratch every time. Plan for changes and renewals in advance to avoid losing overseas sales due to expired certificates.

AIMEILI's consulting services can provide target-country regulatory research, pre-assessment, and pre-communication support when classification is uncertain, helping companies reduce rework before submission. We advocate replacing the outdated “develop first, certify later” model with a “regulatory-driven development logic,” enabling products to meet overseas regulatory expectations from the R&D stage.

Frequently Asked Questions

FAQ 1: In the EU and the US, what class does a common “electrotherapy device” in rehabilitation equipment fall into?

An electrotherapy device stimulates nerves or muscles through electric current and is an energy treatment device. Under EU MDR rules, it is generally classified as Class IIa or IIb, depending on whether it has risk-control functions. Under the US FDA, most electrical stimulators are Class II and require a 510(k) submission. Companies need to provide electromagnetic compatibility, electrical safety, and biocompatibility reports, and explain the therapeutic effects in the clinical evaluation.

FAQ 2: If my rehabilitation device is already CE Class I, does that mean it is definitely low risk in Southeast Asian countries?

No. CE Class I devices are generally low risk, but Southeast Asian countries may refer to IMDRF or FDA classification logic. For example, a CE Class I powered patient lifter may be classified as Class B or Class C in Indonesia or Malaysia, requiring additional clinical evidence consistent with the risk and intended use. Companies must confirm on a country-by-country basis and cannot replace local classification with CE classification.

FAQ 3: Does software-based rehabilitation training tools need to be registered?

If the software itself provides rehabilitation training decisions, dose adjustments, or health risk warnings, most countries will regulate it as medical device software. The EU MDR classifies certain medical software as Class I, but in practice it is often higher, depending on risk and intended use. The US FDA generally manages digital health products used for assessment or treatment as Class II or Class I, but a premarket notification may be required. Companies should prepare software descriptions, clinical validation, and cybersecurity documentation, and determine whether the software should be registered independently or together with the hardware.

Continue Reading

Previous: None

Next: What are the common reasons for supplementary information requests in overseas registration of rehabilitation devices?

Recommended reading: What are the requirements for risk management documents in overseas registration of rehabilitation devices? | How to prepare clinical evaluation data for overseas registration of implantable products? | How to prepare registration documents for overseas registration of implantable products? | How to localize labels and instructions for use for implantable products? | Can test reports be reused for overseas registration of implantable products?

Back to FAQ Center | News | Contact AIMEILI

Content Review and Applicability

Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI International Medical Device Registration Project Team

Source Principle: Priority given to official regulatory bodies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only for auxiliary judgment.

Applicability: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace formal requirements, testing conclusions, or legal advice from target country regulatory authorities.